For patient support groups and advocates to share their stories, best practices, collaborate and get involved.
Today’s podcast covers my conversation with Jill Sisco, president of the Acromegaly Community, about the recent meetings with the Food and Drug Administration (FDA), the US governmental entity responsible for approving new medications. Our conversation focuses on the original meeting held in 2021 and a recent listening session where the AC provided additional feedback to the FDA.
A frank, enlighting discussion about 20 seconds that turn your life around or can affect the way you live it. Are there any of those moments in your life? In today’s podcast, we learn about
An effort is under way to enable Acromegaly patients and doctors to make congress more aware of the needs of patients suffering from this disease. More details on this effort will be forthcoming soon. One
Today we begin a new series of feature articles that highlight the tireless work that people do to help others. Here are three amazing human beings: Jill Sisco runs the Acromegaly Community website and
We know that the increased awareness of pituitary disease is directly related to the higher probability of early diagnosis. Early diagnosis means quality of life, and in many cases increased life expectancy. Awareness is power
CLIK HERE TO DOWNLOAD THE “PATIENT VIEWS AND PERSPECTIVES” COMPILATION FROM PITUITARY WORLD NEWS. From Jorge D Faccinetti – co-founder Pituitary World News – Rare diseases, particularly those that come from the pituitary, are
In October 2014 Dr. Lewis Blevins, Medical Director of the California Center for Pituitary Disorders and Professor of Clinical Medicine and Clinical Neurological Surgery at the University of California San Francisco, and I founded Pituitary World
First, I know “think different” is bad grammar as it should be “think differently”, but it really says it, doesn’t it? A few years ago, 1998 to be exact, Apple, Inc., (the then computer company)
From J D Faccinetti – There are several expert sources that have focused research on the prevalence of pituitary tumors. Estimates on these studies varied from as high as 30 percent to as low